Drug intelligence / Profile preview

desmopressin sandoz

Development stage
Unknown
Lead developer
Sandoz
Modality
Peptides
Administration
Oral
01

Overview

Desmopressin Sandoz is a synthetic peptide analogue of the natural pituitary hormone arginine vasopressin (antidiuretic hormone). It functions as a selective agonist for the vasopressin V2 receptors located primarily in the collecting ducts of the kidneys. By binding to these receptors, desmopressin stimulates the translocation of aquaporin-2 channels to the apical membrane, significantly increasing water permeability and reabsorption. This results in a concentrated urine and a reduction in total urine volume. Unlike natural vasopressin, desmopressin has minimal activity at V1 receptors, meaning it does not typically cause significant vasoconstriction or increase blood pressure at therapeutic doses. It is primarily indicated for the treatment of primary nocturnal enuresis (bedwetting) in children and adults, central diabetes insipidus, and nocturia in adults.

Brand names
Desmopressin Sandoz
02

Targets

AVPR1B (Vasopressin V1b Receptor)AVPR2 (Arginine vasopressin V2 receptor)

Beyond the preview

Go deeper on desmopressin sandoz.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on desmopressin sandoz.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call